^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1335P - Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial

Published date:
09/14/2020
Excerpt:
We explored efficacy and safety of C plus A in a single arm proof of concept study in relapsed NSCLC….Among R pts, we found one STK11/TP53 co-mut, and CHK2/ATM/BRCA2 co-mut and MDM2 mut in those 2 pts previously treated with anti-PD1, respectively.